2 results
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.
Approved WMOCompleted
Primary objective:• To investigate whether Enhanced programming is safe for primary and secondary prevention patientsSecondary objectives:• Investigate the impact of Enhanced programming on adverse events (related to ICD shock with consequences and…